ClinicalTrials.gg
CompletedNCT01461057JOSHUAUpdated Aug 9, 2018Results posted

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

A Phase 2 interventional study of Capecitabine and Cisplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 24 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Stomach Neoplasms by Hoffmann-La Roche — none open to participants now, 2 under way, none of them phase 3. Stomach Neoplasms · Hoffmann-La Roche.

Enrollment
20th of 23
30 · median 158
Started
2011
with 3 others
Phase 2
11 of 29
none open now
Registered
9th of 29
by date

Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 2, and was the 9th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 29 studies in Stomach Neoplasms by Hoffmann-La Roche is open now. The open studies under Stomach Neoplasms, anywhere →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Stomach Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This randomized, multicenter, open-label study will evaluate two different doses of pertuzumab in combination with Herceptin (trastuzumab) and chemotherapy in the first-line treatment of participants with metastatic HER2-positive adenocarcinoma of the stomach or gastroesophageal junction. Participants will be randomized in a 1:1 ratio to two treatment arms. Participants in the Pertuzumab 840/420 mg Arm will receive a pertuzumab loading dose of 840 mg for Cycle 1 and a dose of 420 mg for Cycles 2-6, and participants in the Pertuzumab 840/840 mg Arm will receive pertuzumab 840 mg for all six cycles. Participants in both treatment arms will receive trastuzumab, cisplatin, and capecitabine.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, greater than or equal to (>=) 18 of age
  • Adenocarcinoma of the stomach or gastroesophageal junction with inoperable locally advanced or disease, not amenable to curative therapy
  • , according to the (RECIST), v1.1
  • -positive tumor
  • (ECOG) Performance Status of 0 or 1
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for advanced or disease (except (prior or neoadjuvant therapy at least 6 months before enrollment in the study)
  • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome
  • Active (significant or uncontrolled) gastrointestinal bleeding
  • Abnormal laboratory values
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pertuzumab 840/420 mg

    Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m\^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.

    Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Pertuzumab 840/840 mg

    Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m\^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.

    Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • 1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle

    Also known as: Xeloda

  • 80 mg/m2 on Day 1 of each cycle

  • loading dose of 840 mg, then 420 mg once every three weeks

    Also known as: Perjeta

  • 840 mg once every three weeks

    Also known as: Perjeta

  • loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)

    Time frame: Day 43

  2. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.

    Time frame: From randomization of first participant to end of study (approximately 6 years)

07

Results

Posted Jun 27, 2016

Participant flow

Participant flow — Overall Study
MilestonePertuzumab 840/420 mgPertuzumab 840/840 mg
Started1515
Completed00
Not completed1515
Withdrew: Death109
Withdrew: Withdrawal by subject23
Withdrew: Physician decision02
Withdrew: Adverse event01
Withdrew: Progression of disease10
Withdrew: Study terminated by sponsor20

Outcome measures

PrimaryPercentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)
Time frame:
Day 43
Reported as:
Number · percentage of participants
Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)
percentage of participantsPertuzumab 840/420 mgPertuzumab 840/840 mg
Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)91.6 (78.3 to 99.2)98.3 (91.4 to 99.97)
PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.

Time frame:
From randomization of first participant to end of study (approximately 6 years)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPertuzumab 840/420 mgPertuzumab 840/840 mg
Number of Participants With Adverse Events (AEs)1515

Adverse events

Collected over From randomization of first participant to end of study (approximately 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab 840/420 mg10/15 (66.7%)11/15 (73.3%)15/15 (100%)
Pertuzumab 840/840 mg9/15 (60%)10/15 (66.7%)15/15 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPertuzumab 840/420 mgPertuzumab 840/840 mg
Febrile neutropeniaBlood and lymphatic system disorders4/150/15
DiarrhoeaGastrointestinal disorders2/153/15
VomitingGastrointestinal disorders2/150/15
AstheniaGeneral disorders2/150/15
Mucosal inflammationGeneral disorders2/150/15
Neutrophil count decreasedInvestigations2/150/15
HyponatraemiaMetabolism and nutrition disorders2/150/15
Cardiac failure acuteCardiac disorders1/150/15
AscitesGastrointestinal disorders1/150/15
DyspepsiaGastrointestinal disorders0/151/15
Most frequent other events
Showing 10 of 180
Most frequent other events
EventPertuzumab 840/420 mgPertuzumab 840/840 mg
DiarrhoeaGastrointestinal disorders14/1511/15
NauseaGastrointestinal disorders11/1513/15
AnaemiaBlood and lymphatic system disorders9/1511/15
Neutrophil count decreasedInvestigations11/1511/15
Decreased appetiteMetabolism and nutrition disorders11/159/15
StomatitsGastrointestinal disorders9/156/15
VomitingGastrointestinal disorders9/153/15
HypomagnesaemiaMetabolism and nutrition disorders8/153/15
DizzinessNervous system disorders8/153/15
FatigueGeneral disorders5/157/15

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pertuzumab 840/420 mgPertuzumab 840/840 mgTotal
18 - 40 years213
41 - 64 years4913
Greater than or equal to (>=) 65 years9514
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab 840/420 mgPertuzumab 840/840 mgTotal
Female156
Male141024
08

Study locations

24 sites
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Masaryk Memorial Cancer Institute; Oncological Clinic
    Brno, 656 53, Czechia
  • Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Olomouc; Onkologicka klinika
    Olomouc, 779 00, Czechia
  • Fakultní Nemocnice V Motole; Radioterapeuticko-Onkologicke Oddeleni
    Praha 5, 150 06, Czechia
  • University Hospital Na Bulovce; Institut of Radiation Oncology
    Praha 8, 180 81, Czechia
  • Hopital Morvan
    Brest, 29200, France
  • CRLCC Val dAurelle Paul Lam
    Montpellier cedex 5, 34298, France
  • Hopital Robert Debre; DERMATOLOGIE
    Reims, 51092, France
  • Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
    Berlin, 10117, Germany
  • Klinikum Braunschweig; Medizinische Klinik III; Klinik für Hämatologie und Onkologie
    Braunschweig, 38114, Germany
  • Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
    Frankfurt, 60488, Germany
  • Klinikum Mannheim III. Medizinische Klinik
    Mannheim, 68167, Germany
  • Campus Universitario S.Venuta; Centro Oncologico T.Campanella
    Catanzaro, Calabria 88100, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
    Milano, Lombardia 20133, Italy
  • A.O. Universitaria Pisana; Oncologia
    Pisa, Toscana 56100, Italy
  • Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
    Seoul, 03080, Korea, Republic of
  • Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center; Medical Oncology
    Seoul, 05505, Korea, Republic of
  • Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde
    Maastricht, 6229 HX, Netherlands
  • Hospital del Mar; Servicio de Oncologia
    Barcelona, 08003, Spain
  • Hospital Universitario La Paz; Servicio de Oncologia
    Madrid, 28046, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Mar 2015, 38 months.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 38 months is close to that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2011
First posted
Oct 27, 2011
StartActual
Dec 6, 2011
Primary completionActual
Mar 1, 2015
CompletionActual
Oct 31, 2017
Results first posted
Jun 27, 2016
Last update
Aug 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01461057
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 27, 2011
Start date
Dec 6, 2011
Primary completion
Mar 1, 2015
Completion
Oct 31, 2017
Results posted
Jun 27, 2016
Last update
Aug 9, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion